The initial stage of kidney disease doesn't come up with any symptom. However, there is a beauty in this word "stage". To that end, if there is a stage 1 kidney disease, you can expect that there is going to be a stage 2 soon if you are not careful. To that end, the purpose of this blog is to educate you about the stage 1 kidney disease and it's hard to notice symptoms and then we are going to dive into some treatment options as well.
Germany's Boehringer Ingelheim said on Thursday (Aug 17) it would conduct three late-stage studies for its obesity drug candidate after it showed up to
19 per cent weight loss after 46 weeks in a mid-stage trial.
The private company plans to start enrollments for the trial of the drug, survodutide, which it co-invented with Danish biotech company Zealand Pharma, before
the end of the year.
The trials will evaluate the drug's safety and efficacy, Boehringer said, and added that it would provide further details on the studies before initiation.
Boehringer and Zealand are among global drugmakers racing to grab a share of the potential $100 billion market for obesity treatments within a decade.
Survodutide works by mimicking a gut hormone called glucagon-like peptide-1 (GLP-1), which suppresses appetite, as well as imitating another gut hormone called
glucagon that helps break down fat.
AstraZeneca on Wednesday (April 5) said a combination of its cancer drugs Imfinzi and Lynparza met the main goal in a late-stage trial in patients with
advanced ovarian cancer.
The drugmaker said treatment with a combination of those drugs, along with chemotherapy and bevacizumab - the existing standard of care - improved progression-free
survival in newly diagnosed patients with advanced ovarian cancer without certain mutations.
Lynparza is jointly developed with U.S.-based Merck & Co as a treatment for breast cancer in early stage with certain mutations. Imfinzi alone, along with
chemotherapy and bevacizumab, did not reach statistical significance in its interim analysis, the drugmaker added.
Philipp Harter, director, Department of Gynaecology and Gynaecologic Oncology, Evangelische Kliniken Essen-Mitte, Germany and principal investigator for the trial,
said: "DUO-O showcases the power of academia and industry collaboration in advancing new treatment combinations for patients with ovarian cancer. I'm grateful for
the academic cooperative study groups and patients around the world that made this trial possible and look forward to sharing the results with the clinical community."
Susan Galbraith, executive vice president, Oncology R&D, AstraZeneca, said: "While there has been significant progress for patients with advanced ovarian cancer, an
unmet need still remains. These data from the DUO-O trial provide encouraging evidence for this this Lynparza and Imfinzi combination in patients without tumour
BRCA mutations and reinforce our continued commitment to finding new treatment approaches for these patients. It will be important to understand the key secondary
endpoints as well as data for relevant subgroups."
The global end stage renal disease market size was valued at USD 74.5 billion in 2020 and is expected to expand at a compound annual growth rate (CAGR) of 12.7% from 2021 to 2028
People who don't receive HIV treatment will typically proceed into three stages. But HIV medication can reduce or halt the rise of the disease. With the improvements in treatment, advance to Stage 3 is now less than in the initial days of HIV.
For More Information Visit Our Website
https://drpounders.com/
or Call Us at 214-520-8833
Denmark's Zealand Pharma and Boehringer Ingelheim said their experimental obesity treatment achieved up to 14.9% weight loss in a mid-stage trial, lining up
a potential contestant in the booming obesity drug market.
In a statement on Wednesday (May 10), the partners said that the Phase II dose-finding trial met its primary endpoint of weight loss after 46 weeks.
Paola Casarosa, head of therapeutic areas at Germany's Boehringer Ingelheim told Reuters the partners are in discussion with regulators about the design of a
planned follow-up trial in the third and last phase of testing.
The enormous demand for weight-loss treatments such as Novo Nordisk's Wegovy, or potentially Eli Lilly's Mounjaro, could support as many as 10 competing products
with annual sales reaching up to $100 billion within a decade, mostly in the United States, industry executives and analysts said.
Lilly said about a year ago that Mounjaro was shown to reduce up to 22.5% in weight after 72 weeks of treatment in a much larger late-stage trial.
AstraZeneca said on Thursday (June 30) that a combination of its cancer drug, Imfinzi, and chemotherapy showed promise in a late-stage trial in patients with
an aggressive form of lung cancer, when given before surgery.
Data showed the combination was more effective in removing cancer cells in tissue samples taken during surgery when compared with just chemotherapy in patients with
non-small cell lung cancer, the drugmaker said.
The interim result is a boost to the company's oncology efforts - a major area of focus - following disappointing data for Imfinzi earlier in the year in another
area of therapy.
AstraZeneca added the trial would continue as planned to assess the additional main goal of event-free survival, and the interim data would be shared with health
authorities globally.
Imfinzi belongs to the immunotherapy class of treatments, which boost the body's defences to fight cancer by using antibodies that block or bind to foreign
substances in the body. The treatment generated $2.41 billion in 2021 sales.
Reckitt has recalled certain catches of Nutramigen LGG stage 1 and stage 2 Hypoallergenic Formula powders over the possible presence of Cronobacter sakazakii.
While the products, which are used for special medical purposes for infants, are mainly prescribed, they are also available without a prescription.
The precautionary step has been taken after an isolated overseas sample of the product tested positive for Cronobacter sakazakii, said the consumer goods company,
adding that a thorough investigation is on.
Cronobacter sakazakii is a type of bacteria that can easily survive in dry foods, like powdered infant formula, powdered milk, herbal teas, and starches.
The NHS England is rapidly expanding the targeted lung health check programme (TLHC) across England to detect lung cancers at an early stage.
Launched in 2019, it is a national scheme that identifies people aged 55-74 at increased risk of lung cancer to invite them for a lung health check and chest
CT scan, if appropriate.
Since then, it has heled detect over 3,000 lung cancers, mostly at an early stage when the condition is more treatable, Dr Jason Page, Clinical Director of South
Yorkshire and Bassetlaw targeted lung health checks, revealed in a blog on the NHS website.
The decision to initiate the programme follows a study that showed CT screening reduced lung cancer mortality by 26 per cent in men and between 39 per cent and
61 per cent in women.
In the early stages, testicular cancer does not exhibit any symptoms. In the advanced stages of mestastatic testicular cancer the symptoms might include discomfort and lower back pain, hard to urinate, breathing and cough problems.
Breast cancer treatment is affordable, accessible and of high quality in India as compared to other countries. Not all, but a majority of women are more susceptible to breast cancer than any other types of cancers. It is a common medical condition that can be cured with chemotherapy or radiation therapy when diagnosed in the initial stage. But if detected at the end-stage, it could prove to be life-threatening.
Sun Pharma has announced that it will acquire all outstanding shares of Concert Pharmaceuticals through a tender offer for an upfront payment of $8.00 per
share of common stock in cash, or $576 million in equity value.
The upfront payment of $8.00 per share of common stock in cash represents a premium of approximately 33% to Concert's 30-day volume weighted average price as of
January 18, 2023, the last trading day prior to today's announcement.
Concert is a late-stage biotechnology company pioneering the use of deuterium in medicinal chemistry. Concert has an extensive patent portfolio, including its lead
product candidate deuruxolitinib - an oral inhibitor of Janus kinases JAK1 and JAK2 for the treatment of Alopecia Areata, an autoimmune dermatological disease - which
is in late-stage development.
It has completed the evaluation of the efficacy and safety of deuruxolitinib in adult patients with moderate to severe Alopecia Areata in its THRIVE-AA Phase 3
clinical program and two open label, long-term extension studies are ongoing in North America and Europe. Sun Pharma's immediate focus would be to follow Concert's
plan to submit a New Drug Application (NDA) to the U.S. Food and Drug Administration (FDA) in the first half of 2023.
Pfizer said on Thursday (June 1) data from late-stage trials showed its experimental combination of antibiotics was effective in treating deadly infections caused by drug-resistant bacteria.
Deaths from antibiotic-resistant bacteria, also known as superbugs, have been on the rise globally, and health regulators have called for the development of newer
treatments as resistance to older antibiotics grows.
The late-stage studies compared the experimental combination of the antibiotics aztreonam-avibactam (ATM-AVI) and existing generic drug metronidazole with a
combination of two older antibiotics - meropenem and colistin - to treat complicated intra-abdominal infections and types of hospital-acquired pneumonia.
Hospital-acquired pneumonia occurs in patients at least two to three days after being admitted, or in those who have life-threatening lung infections with high
mortality rates and who are on mechanical breathing machines.
Pfizer said the data from the studies shows the antibiotic combination of ATM-AVI is effective and well-tolerated in treating infections caused by gram-negative
bacteria.
The cure rate in patients with complicated intra-abdominal infections with Pfizer's combination therapy, along with existing generic drug metronidazole, was 76.4%,
versus 74% using the other antibiotics.
An experimental Alzheimer's drug developed by Eli Lilly and Co slowed cognitive decline by 35% in a late-stage trial, the company said on Wednesday, providing
what experts say is the strongest evidence yet that removing sticky amyloid plaques from the brain benefits patients with the fatal disease.
Lilly's drug, donanemab, met all goals of the trial, the company said. It slowed progression of Alzheimer's by 35% compared to a placebo in 1,182 people with
early-stage disease whose brains had deposits of two key Alzheimer's proteins, beta amyloid as well as intermediate levels of tau, a protein linked with disease
progression and brain cell death.
The study also evaluated the drug in 552 patients with high levels of tau and found that when both groups were combined, donanemab slowed progression by 29% based
on a commonly used scale of dementia progression known as the Clinical Dementia Rating Scale (CDR-SB).
Using that scale, experts said Lilly's findings were roughly on par with Eisai Co Ltd and Biogen Inc's lecanemab, sold under the brand name Leqembi, which reduced
cognitive decline by 27% in patients with early Alzheimer's in a study published last year.
The results drove Lilly's shares to a record high, up more than 6% at $429.85.
Dr. Ronald Petersen, an Alzheimer's researcher at Mayo Clinic, said Lilly's trial is the third to show removing amyloid from the brain slows progression of the
disease, which could put to rest some lingering doubts about the benefits of drugs in the class and the amyloid-lowering theory.
"It's modest, but I think it's real," he said of the benefit, "and I think it's clinically meaningful."
Dr. Erik Musiek, a Washington University neurologist at Barnes-Jewish Hospital, said the efficacy looks as good or better than lecanemab.
UK regulator has approved a second oral antiviral for early treatment of Covid-19 in high-risk adults, after molnupiravir.
The Medicines and Healthcare products Regulatory Agency (MHRA) gave its nod for a new treatment called Paxlovid (PF-07321332 and ritonavir), after finding it safe and effective at reducing the risk of hospitalisation and death in people diagnosed with mild Covid-19 infection.
Developed by Pfizer, Paxlovid prevents the multiplying of virus, helping the body to overcome the infection.
A clinical trial for the treatment in high risk individuals revealed that a five-days course of Paxlovid reduces the risk of hospitalisation and death by 89 per cent.
It further revealed that Paxlovid is most effective when taken in the early stage of infection.
Dr June Raine, MHRA chief executive, said: "We now have a further antiviral medicine for the treatment of Covid-19 that can be taken by mouth rather than administered
intravenously. This means it can be administered outside a hospital setting, before Covid-19 has progressed to a severe stage."
Working towards its five-year strategy, the Royal Pharmaceutical Society (RPS) has put some plan in place to change its existing structure at the executive level, which could potentially render some senior positions redundant.
Though the process is in nascent stage, "two roles have been identified at potential risk of redundancy," RPS said in a statement on Thursday (March 3) afternoon, adding: "This is very much at proposal stage and no final decisions or outcomes have been reached."0
It didn't specify which two roles were going to be axed, saying: "We are unable to go into the specifics of the process for individuals due to its confidential nature, but we will of course go through a fair, reasonable and confidential consultation process and are supporting the individuals involved.
"No one should be in any doubt that our commitment to education and the profession's development remains the highest priority for us, and equally support for our members, thought leadership and advocacy are core to what we do as a professional leadership body."